Sudan imported $30 mln of malaria drugs in 2025, regulator says

January 10, 2026 (KHARTOUM) – Sudan spent $30 million on imported malaria medicines in 2025, a senior regulatory official said on Saturday, after shortages were reported in Khartoum and other states during the final months of the year.

The figure covers shipments arranged by the National Medicines and Poisons Board (NMPB) to replenish stocks depleted by conflict-related supply disruptions, Mohamed Bashir, the board’s secretary, told Sudan Tribune.

“The consignments have been distributed to all 18 states, and current inventory covers projected demand for the peak transmission season,” Bashir said.

A Ministry of Health bulletin on Dec. 24 warned of “critical gaps” in artemisinin-based combination therapies, while the Sudan Doctors’ Trade Union recorded 2,000 malaria cases and 80 associated deaths in November and December.

Bashir said the NMPB had stepped up post-market surveillance to curb sub-standard products and was running workshops to enforce national treatment guidelines. He added that inappropriate drug use was fuelling parasite resistance and reducing cure rates.

The World Health Organization estimates that 70 per cent of health facilities in conflict-affected areas are no longer functional, while 45 per cent in more stable regions face shortages of staff, fuel and supplies.